ARTICLE | Company News

Amgen sales and marketing update

December 13, 2010 8:00 AM UTC

Amgen expanded its First Step Program to include commercially insured patients. The program will help eligible patients in the U.S. outside of Massachusetts with their deductible, co-insurance or co-pay requirements for Neulasta pegfilgrastim, Nplate romiplostim, and Xgeva denosumab regardless of income. Patients will not be responsible for out-of-pocket costs for the first Nplate or Neulasta treatment associated with a new treatment regimen and will pay a maximum of $25 for subsequent injections. Maximum benefits per patient are $5,000 per six month period. ...